Laredo Laguna

Laguna Clinical Research Associates

COVID-19

Hypertension

Cancer

Hematologic Cancer

Remdesivir

IONIS-AGT-LRx

KPG-818

Gilead Sciences

Ionis Pharmaceuticals

Kangpu Biopharmaceuticals

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels.

Indication: Hematological malignancies (multiple myeloma \[MM\], mantle cell lymphoma \[MCL\], diffuse large B-cell lymphoma \[DLBCL\], adult T-cell leukemia-lymphoma \[ATL\], and indolent non Hodgkin lymphomas such as follicular lymphoma \[FL\] and chronic lymphocytic leukemia \[CLL\]/small lymphocytic lymphoma \[SLL\]).

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Laguna Clinical Research Associates | Laredo Laguna

Site insights

Work at this site?

Active trials

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Trial sponsors